BIO KEY INTERNATIONAL INC (BKYI)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-29

Key Insights

BIO-key implemented a 1-for-10 reverse stock split effective April 29, 2026, reducing outstanding shares from approximately 10.9 million to 1.1 million, a significant capital structure change that typically signals financial distress or an attempt to meet minimum stock price requirements.
The reverse split ratio of 1-for-10 was selected at the lower end of the authorized 1-for-2 to 1-for-10 range, suggesting the Board chose a more aggressive consolidation despite having discretion for a milder approach, indicating urgency around stock price recovery.
The company will trade under a new CUSIP number (09060C606) beginning April 30, 2026, with trading resuming on a split-adjusted basis, which may result in initial trading volatility and warrant attention to liquidity and pricing implications.
This action was approved by stockholders on April 20, 2026, demonstrating shareholder support, though reverse splits are often viewed negatively by the market as they typically precede companies with declining valuations or compliance issues.

Current Report Filed: 2026-04-24

Key Insights

Stockholders approved a reverse stock split with a flexible ratio of 1-for-2 to 1-for-10, giving the Board discretion to determine the exact ratio and timing by May 6, 2026, which is typical for companies seeking to increase share price and improve listing compliance.
The proposal passed with strong majority support (75.5% of votes cast in favor), indicating stockholder confidence in management's decision, though 24.5% opposition suggests some investor concern about the reverse split strategy.
Quorum was achieved with 51.62% of outstanding shares represented, meeting the minimum threshold required for the special meeting, enabling the company to proceed with implementing the authorized reverse split.

Current Report Filed: 2026-04-22

Key Insights

BIO-key International failed to timely file its Annual Report on Form 10-K for fiscal year 2025, triggering a Nasdaq listing rule non-compliance notice under Rule 5250(c)(1).
The notification has no immediate effect on listing or trading status, but the company faces potential delisting risk if the 10-K filing is not completed within the regulatory cure period (typically 60 days).
This regulatory failure suggests potential operational or financial reporting challenges that prevented timely disclosure, raising concerns about management's ability to execute basic compliance requirements and potentially masking underlying business problems.

Current Report Filed: 2026-03-31

Key Insights

BIO-key International, Inc. reported its financial results for the fourth quarter and full year 2025, indicating the company's operational and financial performance during that period.
The company did not provide any additional details or commentary on the reported results, so investors may need to further analyze the press release to understand the key drivers and implications for the business.
As an 8-K filing, this report is likely disclosing a material event or information, but without more context, the significance to investors is unclear.

Current Report Filed: 2026-03-04

Key Insights

BIO-key International, Inc. reported its year-end 2025 cash position, which is a key financial metric for investors to assess the company's liquidity and ability to fund operations.
The company did not provide any additional information about its financial performance or business updates, limiting the insight that can be gleaned from this filing.
Investors will likely need to wait for the company's next scheduled earnings report or other disclosures to gain a more comprehensive understanding of BIO-key's recent performance and outlook.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.